BioVie to Present at Cantor Virtual Global Healthcare Conference
BioVie Inc. (NASDAQ: BIVI) announced its management team's participation at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. A presentation is scheduled for September 29, 2021, at 11:20 a.m. EST, with a webcast available for investors. BioVie, focused on innovative therapies for neurological and liver diseases, is also progressing its Phase 2 study for its Orphan drug candidate BIV201 and initiating a Phase 3 study for NE3107 in Alzheimer's disease. More details can be found on their website.
- None.
- None.
SANTA MONICA, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021.
Details on the conference can be found below.
Cantor Virtual Global Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: Wednesday September 29, 2021
Presentation Time: 11:20 a.m. EST
Webcast: https://wsw.com/webcast/cantor12/bivi/2076900
An archived webcast will also be accessible in the Investors section of the company’s website at www.bioviepharma.com.
About BioVie
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022. The Company is also planning a pivotal Phase 3 study of BIV201 in the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) in 2022. BIV201 is administered as a patent-pending liquid formulation. The active agent is approved in about 40 countries for related complications of advanced liver cirrhosis but is not available in the US or Japan. In neurodegenerative disease, BioVie acquired the assets of NeurMedix Inc., including NE3107 that inhibits inflammatory activation of ERK and NFB (e.g. TNF transcription) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g. insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate NE3107 in subjects who have mild to moderate Alzheimer's disease (NCT04669028). An estimated six million Americans suffer from Alzheimer’s. BioVie has initiated this study and is targeting primary completion in late 2022. A Phase 2 study of NE3107 in Parkinson’s disease is planned to start later this year, and related compounds have additional potential to treat certain cancers. NE3107 is patented in the United States, Australia, Canada, Europe and South Korea. For more information, visit http://www.biovieinc.com/.
Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our clinical studies and to obtain approval for our product candidates, to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.
For Investor Relations Inquiries:
Contact:
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What is BioVie Inc. presenting at the Cantor Virtual Global Healthcare Conference?
When is BioVie scheduled to present at the Cantor Conference?
What is the focus of BioVie Inc.'s clinical studies?
What is the status of BioVie’s drug candidate BIV201?
What is the planned timeline for BioVie’s Phase 3 study of NE3107?
